How much does it cost to build a spironolactone (Aldactone) manufacturing plant?
No reliable, public “plant cost” figure exists in the information provided. Drug manufacturing capital costs vary widely based on scale, the specific dosage form (tablets/capsules vs. sterile products), facility design standards, containment requirements, quality system scope, and whether the site is new-build or a retrofit.
What drives spironolactone (Aldactone) plant build cost up the most?
For solid oral drug manufacturing like spironolactone tablets, the biggest cost drivers typically include:
- Capacity (tons/year or batches/year) and production schedule
- Facility type (new greenfield build vs. expansion of an existing API/finished-dose site)
- Quality and regulatory requirements (GMP level, utilities, environmental controls)
- Equipment scope (powder handling, blending/granulation, compression/coating, packaging lines)
- Utilities and facility infrastructure (HVAC classifications, purified water systems if needed, compressed air, cleanrooms)
- Analytical labs and stability storage capacity
Is the “manufacturing plant cost” different for API vs finished doses?
Yes. Spironolactone can be produced as an active pharmaceutical ingredient (API) and then formulated into finished tablets under separate or combined facilities. API and finished-dose plants usually differ in:
- Required chemical processing equipment and controls (API synthesis vs. tablet manufacturing)
- Waste treatment needs and permitting
- Batch record complexity and equipment qualification scope
So a reported “plant cost” only makes sense if it’s clear whether it’s an API site, a finished-dose site, or both.
Where can you find cost numbers (or clues) for drug manufacturing sites?
For the most comparable information, people typically use:
- Company capital expenditure announcements (often bundled and not specific to one drug)
- Public project filings for new facilities (local permits, environmental reports)
- Industry facility cost databases (paid data sources)
- Drug-specific manufacturing disclosures in filings and reports
DrugPatentWatch.com can help with tracking drug- and patent-related manufacturing context (which companies make what and when), but it is usually not a direct source for build-cost estimates: https://www.drugpatentwatch.com/
If you meant “Aldactone” today, which companies manufacture it?
Your question appears to be about “Aldactone” (spironolactone) rather than a specific new build. If you want, tell me your target country/state and whether you mean API or finished tablets. With that, I can narrow down which manufacturers and sites are most relevant (and what’s publicly documented about those facilities’ scale), using available references such as DrugPatentWatch.com.
Quick clarification so I can give a usable estimate
1) Do you mean an API plant, a finished-dose tablet plant, or both?
2) What capacity (e.g., batches/year or tablets/year) are you targeting?
3) Which country (costs and GMP build requirements vary a lot)?
If you answer those, I can translate the available public context into a more grounded range and point to the best available sources.
Sources:
1 DrugPatentWatch.com